Combining pioneering scientific discovery with over two decades of international industry experience to accelerate cell-free therapeutic breakthroughs.
Legacinetics was founded by Professor Rajneesh Verma PhD, and James Scuderi, who together lead a team of highly experienced scientists, technicians and regenerative health practitioners from across the world.
Professor Rajneesh Verma is a globally recognised reproductive biotechnologist and stem cell scientist. He earned his PhD from Monash University (Australia) and was selected to collaborate directly with Nobel Laureate Prof. Shinya Yamanaka in 2012 at Kyoto University. His work with Nobel Laureate Yamanaka was centred on on iPSC development, working as a lead Researcher on the Sickle Cell Anaemia project, and related fields of advanced stem-cell therapies. He has held leadership roles at Gyeongsang National University (Korea), Mahidol University (Thailand), and University of Oslo (Norway), where he continued the development and refinement of advanced differentiation protocols, specialising in exosome and extra-cellular vesicle therapy.
Professor Verma serves as Director and Chief Scientific Director and Co-Founder of GLOSTA Sciences Management (UAE), and consults globally to leading clinicians and critical care specialists on the application of advanced stem-cell therapies and IPSC derived scientific advancements. He has developed multiple IP assets that underpin Legacinetics’ autologous and allogeneic exosome platforms.
James Scuderi brings over 20 years of global industry experience and oversees commercial strategy, regulatory structuring, and capital deployment.
With directorships across industries including life-sciences, quantitative finance and project development across Australia, China, UAE, New Zealand, and Africa, plus qualifications and formal training in accounting, finance, stem-cell science and genetics, James ensures Legacinetics executes with speed, compliance, and commercial rigour. As Co-Founder of Legacinetics, James brings his wealth of experience, global networks and deep passion for scientific advancement to the fore, building world-leading teams to achieve significant scientific discovery and collaboration.
Bringing together leading minds from around the world, our advisory team guides Legacinetics with deep technical expertise, ensuring our innovation is always backed by scientific integrity & precision.
Professor Paul Verma is Program Leader at the South Australian Research & Development Institute (SARDI), an Adjunct Professorat Monash University, and an Affiliate Professor at the University of Adelaide. With a PhD from the University of Adelaide, he is a reproductive biologist with over 30 years of experience, specialising in advanced reproductive technologies and research translation from humans to livestock , IPSC development and advanced cell sciences.
Throughout his career, he has initiated and led research programs in both corporate and academic settings, notably at Monash, where he became one of the youngest professors in 2008, with his team reporting the first findings on livestock and endangered felid iPSCs. He currently leads livestock research at SARDI, including the development of world-renowned Alzheimer’s Disease models, and has over 100 publications, holds several patents, and has been featured in Nature.
He has edited three books for Springer Nature, New York, focusing on biotechniques to address livestock industry challenges. He collaborates internationally and received the Hind Rattan Award for his research contributions.
Dr. Mann is an internationally renowned Geneticist, having served as Senior Professor at Monash University in the School of Biomedical Sciences. He performs world-leading research on mitochondrial replacement therapy in the Biomedicine Discovery Institute, collaborating with scientific leaders globally on mitochondrial transfer, genetic modeling and epigenetics.
After completing his PhD at University College London, Dr. Mann undertook several roles as Senior Research Fellow, Director and Professor at globally renowned institutions. Dr. Mann currently performs research on mitochondrial replacement therapy at the Biomedicine Discovery Institute, Monash University. He previously led laboratories researching the role of epigenetics in mammalian germ cell development at the City of Hope National Medical Center in Los Angeles, The University of Melbourne, and the Murdoch Children’s Research Institute, Melbourne.
His research highlights include contributions to the establishment of the field of genomic imprinting, the first birth of live mammalian young by sperm microinjection, and the first derivation of mammalian and rogenetic embryonic stem cell lines. He has directed institutional facilities for making preclinical geneticmodels of disease, and for several years instructed the ‘Molecular Embryology of the Mouse Course’ at the Cold Spring Harbor Laboratory, New York. Dr. Mann’s extensive work in highly specialised fields has seen him contribute to more than 100 research papers, and his deep understanding and ongoing work in the field of mitochondrial function places him at the forefront of the Legacinetics pathway to treating Alzheimer’s Disease and other disorders associated with mitochondrial dysfunction.
Professor Bill Ritchie (Dr. William A. Ritchie) is a distinguished Scottish embryologist renowned for his pivotalhands-on role in creating Dolly the Sheep, the first mammal cloned from an adult somatic cell. He began his career in 1972 as a practical agricultural worker in Scotland before earning an Honours degree from the Open University. He later obtained his PhD by publication from a Hungarian University. He advanced throughroles at the Roslin Institute, becoming a skilled embryologist specialising in micromanipulation and nuclear transfer techniques.
Professor Ritchie performed the critical nuclear transfer procedures that produced Dolly in 1996, as well as earlier cloned lambs Megan and Morag (1995) from cultured cells, and subsequent genetically modified clones. His expertise enabled breakthroughs in mammalian cloning and transgenic animal production. Post Roslin, he contributed to the first cloned camel in Dubai and helped establish cloning programmes in Africa, including the first cloned native cattle in Kenya.
His achievements have been recognised with honours including election as a Fellow of the Royal Society of Biology (FRSB). Professor Ritchie’s pioneering work in reproductive biotechnology and animal cloning continues to influence regenerative medicine, stem cell research, and therapeutic applications, positioning him as one of the world’s most consequential contributors to scientific advisory efforts in cloning and celltherapy.
